form10k-a12312007.htm
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-K/A
(Amendment
No. 1)
(Mark
One)
|
ý
|
|
ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
|
|
|
For
the fiscal year ended December 31, 2007
|
|
|
|
OR
|
|
|
|
o
|
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
|
|
|
For
the transition period
from to
|
|
|
|
Commission
file number 0-32501
|
CYTORI
THERAPEUTICS, INC.
(Exact
name of Registrant as Specified in Its Charter)
DELAWARE
|
|
33-0827593
|
(State
or Other Jurisdiction
of
Incorporation or Organization)
|
|
(I.R.S.
Employer
Identification
No.)
|
|
|
|
3020
CALLAN ROAD, SAN DIEGO, CALIFORNIA
|
|
92121
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 458-0900
Securities
registered pursuant to Section 12(b) of the Act:
Title of Each Class
|
|
Name of Each Exchange on Which
Registered
|
Common
stock, par value $0.001
|
|
The
NASDAQ Stock Market LLC
|
Securities
registered pursuant to Section 12(g) of the Act:
None
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in
Rule 405 of the Securities Act. Yes o No ý
Indicate
by check mark if the registrant is not required to file reports pursuant to
Section 13 or Section 15(d) of the Exchange Act.
Yes o No ý
Indicate
by check mark whether the registrant: (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.
Yes ý No o
Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of
Regulation S-K is not contained herein, and will not be contained, to the best
of the registrant’s knowledge, in definitive proxy or information statements
incorporated by reference in Part III
of this Form 10-K or any amendment to this Form 10-K. ý
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of “large accelerated filer,”
“accelerated filer” and “smaller reporting company” in Rule 12b-2 of the
Exchange Act (Check one).
Large
Accelerated Filer o
|
Accelerated
Filer ý
|
Non-Accelerated
Filer o
|
Smaller
reporting company o
|
|
|
(Do
not check if a smaller reporting company)
|
|
Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act). Yes o No ý
The
aggregate market value of the common stock of the registrant held by
non-affiliates of the registrant on June 30, 2007, the last business day of the
registrant’s most recently completed second fiscal quarter, was $96,238,365
based on the closing sales price of the registrant’s common stock on June 30,
2007 as reported on the Nasdaq Global Market, of $5.75 per share.
As of
February 29, 2008, there were 25,103,898 shares of the registrant’s common stock
outstanding.
DOCUMENTS INCORPORATED BY
REFERENCE: None
EXPLANATORY
NOTE
We filed
our Annual Report on Form 10-K for the year ended December 31, 2007 with
the Securities and Exchange Commission on March 14, 2008 (the “Original
Report”). We are filing this Amendment No. 1 to the Original Report
solely to provide revised certifications of our principal executive officer and
principal financial officer attached as Exhibits 31.1 and 31.2 to the Original
Report to add provisions inadvertently omitted from paragraph 4 of these
certifications. This Amendment No. 1 does not reflect events
occurring since the filing of the Original Report and it does not modify, update
or reiterate the financial information or other disclosure provided in the
Original Report.
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, the registrant has duly caused this registration statement to be signed on
its behalf by the undersigned, thereunto duly authorized.
|
CYTORI
THERAPEUTICS, INC.
|
|
|
|
|
By:
|
/s/
Christopher J. Calhoun
|
Dated:
December 17, 2008
|
|
Christopher
J. Calhoun
|
|
|
Chief
Executive Officer
|
|
|
|
|
By:
|
/s/
Mark E. Saad
|
Dated:
December 17, 2008
|
|
Mark
E. Saad
|
|
|
Chief
Financial Officer
|
EXHIBIT
INDEX
Exhibit
Number
|
|
Description
|
31.1
|
|
Certification
of Principal Executive Officer Pursuant to Securities Exchange Act Rule
13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002
|
31.2
|
|
Certification
of Principal Financial Officer Pursuant to Securities Exchange Act Rule
13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002
|
ex311.htm
EXHIBIT
31.1
Certification
of Principal Executive Officer Pursuant to
Securities
Exchange Act Rule 13a-14(a)
As
Adopted Pursuant to
Section 302
of the Sarbanes-Oxley Act of 2002
I,
Christopher J. Calhoun, certify that:
1. I have
reviewed this annual report on Form 10-K of Cytori Therapeutics,
Inc.;
2. Based
on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;
3.
[Intentionally omitted];
4. The
registrant’s other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
(a)
designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
(b)
designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;
(c)
evaluated the effectiveness of the registrant’s disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and
(d)
disclosed in this report any change in the registrant’s internal control over
financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The
registrant’s other certifying officer and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of
directors (or persons performing the equivalent functions):
(a) all
significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and
report financial information; and
(b) any
fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant’s internal control over financial
reporting.
Date:
December 17, 2008
|
/s/
Christopher J. Calhoun
|
|
Christopher
J. Calhoun
|
|
Chief
Executive Officer
|
|
|
ex312.htm
EXHIBIT
31.2
Certification
of Principal Financial Officer Pursuant to
Securities
Exchange Act Rule 13a-14(a)
As
Adopted Pursuant to
Section 302
of the Sarbanes-Oxley Act of 2002
I, Mark
E. Saad, certify that:
1. I have
reviewed this annual report on Form 10-K of Cytori Therapeutics,
Inc.;
2. Based
on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;
3.
[Intentionally omitted];
4. The
registrant’s other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
(a)
designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
(b)
designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;
(c)
evaluated the effectiveness of the registrant’s disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and
(d)
disclosed in this report any change in the registrant’s internal control over
financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The
registrant’s other certifying officer and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of
directors (or persons performing the equivalent functions):
(a) all
significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and
report financial information; and
(b) any
fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant’s internal control over financial
reporting.
Date:
December 17, 2008
|
/s/
Mark E. Saad
|
|
Mark
E. Saad
|
|
Chief
Financial Officer
|
|
|